September 29, 2021

Sinocare présente ses produits pour la gestion du diabète et des maladies chroniques lors de la deuxième exposition économique et commerciale Chine-Afrique

CHANGSHA, Chine, 29 septembre 2021 /PRNewswire/ — Sinocare, le leader mondial du développement de tests médicaux, a présenté sa dernière gamme de produits lors de la deuxième exposition économique et commerciale Chine-Afrique (CAETE), qui s’est tenue du 26 au 29 septembre au centre international de congrès et d’expositions de Changsha. Sinocare a présenté, sur le stand qui lui était réservé, différents types de produits pour la gestion des maladies chroniques, notamment le glucomètre, le tensiomètre, le détecteur de lipides sanguins et le détecteur d’acide urique, et a également dévoilé son analyseur multifonction portable analyseur HbA1C portable et son détecteur par fluorescence de produits finis de glycation avancée.

CAETE est une plate-forme importante pour la Chine et les pays africains pour mener une coopération économique et commerciale, et des échanges et dialogues intéressants. Sous le thème « Nouveau départ, nouvelles opportunités, nouvelles réalisations », l’événement de cette année est axé sur les domaines des produits alimentaires et agricoles, des industries médicales et de santé, de la coopération en matière d’infrastructures et de chaînes industrielles, ainsi que de la coopération économique et commerciale approfondie. Sinocare a présenté un certain nombre de produits de pointe qui favoriseront davantage la coopération entre les secteurs médical et de la santé de la Chine et de l’Afrique, et permettront la construction d’une communauté médicale commune.

« Chez Sinocare, notre vision consiste à fournir des produits et des services de haute qualité aux personnes souffrant de diabète et d’autres maladies chroniques afin de les aider à améliorer leur qualité de vie. Nous avons hâte de travailler avec des professionnels de santé et des entreprises privées en Afrique pour fournir à davantage de personnes des solutions accessibles et abordables pour la gestion du diabète », a déclaré Louis Hu, directeur régional de Sinocare pour l’Afrique.

Lors de la CAETE, Sinocare a lancé ses produits phares pour quatre maladies chroniques : le Gold AQ PLUS et le Safe AQ Smart pour la glycémie, l’AES-U111 pour la pression artérielle ; iCARE2100 pour l’analyse multi-index ; et PCH50 pour l’analyse de l’HbA1C. Avec des caractéristiques et des avantages notables, les produits de Sinocare ont attiré l’attention d’innombrables participants qui se sont arrêtés sur le stand pour une consultation.

Gold AQ PLUS possède des propriétés électrochimiques supérieures et une résistance à la corrosion extrêmement importante avec une bandelette de test d’électrode en or pur à 99,99%. Le système est capable de détecter avec précision la température de l’échantillon de sang, le HCT et la température ambiante, et de corriger automatiquement les écarts de résultat. Son autre glucomètre phare exposé était le Safe AQ Smart, doté d’un système FAD-GDH pour des résultats exacts et précis, d’un système d’exploitation facile d’utilisation qui ne nécessite aucun codage et d’une éjection automatique des bandelettes de test.

Pour les patients présentant un taux de cholestérol élevé, le détecteur de lipides et de glycémie à double usage peut être utilisé pour la mesure quantitative du CT, du HDL, des TG et du GLU. Le détecteur a un débit rapide de glucose en 5s et de lipides en 100s, et prend en charge l’impression en ligne par USB et la transmission de données par Bluetooth. Par ailleurs, le système de surveillance de la glycémie et de l’acide urique à double fonction Safe AQ-UG peut être utilisé pour les personnes souffrant de diabète et d’hyperuricémie. Safe AQ UG respecte la norme ISO15197 2013 et est équipé d’une éjection automatique des bandelettes et d’un code intelligent pour les tests d’acide urique.

En outre, iCARE2100 est l’instrument multiplateforme innovant de Sinocare possédant plusieurs indicateurs pour réaliser des tests pratiques au chevet du patient. Alimenté par la technologie principale Liquid Phase iPOCT, iCARE 2100 prend en charge une haute précision et une détection instantanée. Sans utiliser d’autres consommables, les praticiens peuvent réduire les coûts des tests sans compromettre la qualité.

Au-delà de la Chine, Sinocare est présent dans 42 pays d’Afrique, dont l’Algérie, l’Égypte, l’Éthiopie, l’Afrique du Sud et plus encore. L’ensemble de ses ventes à travers le continent ont atteint plus de 110 millions de yuans, les produits les plus populaires de Sinocare étant les systèmes de surveillance de la glycémie, les tensiomètres, les analyseurs de profil lipidique et les détecteurs de HbA1c. La croissance rapide de Sinocare en Afrique s’explique par ses systèmes indolores et faciles à utiliser qui conviennent à un grand nombre de personnes, ainsi que sa stabilité de prélèvement d’échantillons et de bandelette de test avec une technologie brevetée.

Sinocare continue de se développer activement en Afrique et prévoit de créer des usines de production en Algérie et en Égypte pour réaliser la production locale de bandelettes de test de glycémie. Cette initiative réduira considérablement les coûts et le temps de transport, et accélérera ses capacités à fournir aux populations africaines des produits pour la surveillance du diabète.

À propos de Sinocare :

Sinocare compte 19 ans d’expérience dans le secteur des lecteurs de glycémie depuis sa fondation en 2002. La société se consacre au développement, à la production et à la vente de la détection rapide des maladies chroniques grâce à l’utilisation de la technologie des biocapteurs. En 2016, après avoir acquis avec succès Nipro diagnostic Inc. (maintenant renommée Trividia Health Inc.) et PTS Diagnostics Inc., Sinocare est devenu le numéro 5 mondial des fabricants de glucomètres et l’une des principales sociétés au monde d’appareils de test au point de service.

Pour plus d’informations, veuillez consulter le site : www.sinocareintl.com

Facebook : Sinocare In’tl

Contact pour les médias : Echo Gao
Intl_mkt@sinocare.com

Photo – https://mma.prnewswire.com/media/1637313/Sinocare_Headquarters.jpg

September 29, 2021

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular Injection in Ongoing Phase 2/3 Studies

Data to be Presented During IDWeek 2021 and 19^th Annual Discovery on Target Conference

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the company’s COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the company’s ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America’s IDWeek 2021, being held from Sept. 29 – Oct. 3, 2021. In addition, Adagio’s chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19^th Annual Discovery on Target Conference on Sept. 30, 2021.

“The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 – which was designed to be potent, broadly neutralizing and delivered as a single IM injection – could have on people with or at risk of COVID-19,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19. We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.”

Phase 1 Trial Update
Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. Importantly, ADG20 was well tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts. Participants will continue to be followed through 12 months to assess safety and tolerability, PK, immunogenicity and serum virus neutralizing activity.

Phase 1 Poster Information: (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Dose Selection Strategy
To support dose selection for Adagio’s global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half-life monoclonal antibodies in serum and key sites of viral replication in the respiratory tract. Adagio’s model adequately a priori predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagio’s Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE.

For the STAMP treatment trial, data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads. Further, for the EVADE prevention trial, data compiled to date suggest the 300 mg IM regimen has a projected ability to rapidly exceed target serum concentrations in the majority of simulated patients and to maintain potentially effective concentrations for up to 12 months.

Dose Selection Poster Information

(1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
(1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
(1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)

The STAMP and EVADE clinical trials are currently ongoing and enrolling patients globally. For more information, please visit clincialtrials.gov.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA application, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

September 29, 2021

IRC: 2.1 million Kenyans Face Hunger Due to Drought

The International Rescue Committee says more than two million Kenyans are facing hunger due to poor rainfall. Kenya’s president, Uhuru Kenyatta, declared a national disaster this month because of drought.

Thirty-six-year-old Suleiman Ahmed Osman lost 50% of his livestock to drought in the past six months. He says more are dying now due to worsening drought.

“When we lost this number of animals there is no other source of income,” he said. “To source our daily meal because we used to get milk and meat, sometimes selling the animals to get other food, sugar and other things. Now that the animals are very emaciated, nobody can buy them, no milk because the drought has affected them to the extent that no milk can come from the animal.”

The International Federation of Red Cross and Red Crescent Societies (IFRC) says Kenya received insufficient rainfall during the October to December 2020 and March to May 2021 rainy seasons, leading to the current drought situation.

The IFRC report said that arid and semi-arid areas received less than 50% of the average rainfall in June. The three counties in northeastern Kenya received less than 25% of average rainfall.

Abdullahi Musa has been buying animal feed and water for four months now for his more than 100 cattle in Garissa, along the Kenya and Somalia border.

“There are two sets of livestock herders,” he said. “There are those who the drought in Kenya has affected them there are those who crossed to Somalia to get pasture but came back due to lack of water. I am among the people who are not so affected. I have lost some animals but most of them are alive. But 90% of animal herders have lost their livestock. They got nothing.”

The International Rescue Committee says 2.1 million people in Kenya are now food insecure.

The head of the organization in Kenya, Mohamed El Montassir Hussein, says he is concerned about the growing humanitarian situation in some 20 out of 47 counties.

“Our concern overall is the protracted drought situation and protracted aspect of drought in Kenya that’s been over the years coming again and again and also concern is extended to the growing humanitarian needs as people move out of their homes searching for places closer to water sources,” he said.

The IRC says climate change is the main driver of the region’s recurring drought and locust outbreaks.

Kenya’s National Drought Management Authority predicts the food insecurity situation will persist until the end of the year.

The drought management authority says people’s fortunes may change if the affected areas get rain in the next three months.

Source: Voice of America

September 29, 2021

UN Aid Chief to Ethiopia on Famine in Tigray: ‘Get Those Trucks Moving’

United Nations aid chief Martin Griffiths said on Tuesday he assumes famine has taken hold in Ethiopia’s Tigray where a nearly three-month long “de-facto blockade” has restricted aid deliveries to 10% of what is needed in the war-torn region.

Griffiths told Reuters during an interview that his request was simple: “Get those trucks moving.”

“This is man-made, this can be remedied by the act of government,” he said.

War broke out 10 months ago between Ethiopia’s federal troops and forces loyal to the Tigray People’s Liberation Front (TPLF), which controls Tigray. Thousands have died and more than two million people have been forced to flee their homes.

“We predicted that there were 400,000 people in famine-like conditions, at risk of famine, and the supposition was that if no aid got to them adequately, they would slip into famine,” said Griffiths, referring to a U.N. assessment in June.

“I have to assume that something like that is happening,” he said, adding that it was difficult to know exactly what the situation was on the ground in Tigray because of a de-facto aid blockade and lack of fuel, cash and trucks.

Ethiopia’s U.N. mission in New York said that “any claim on the existence of blockade is baseless.” It said aid groups “faced shortage in trucks as a result of the non-return of almost all trucks that travelled to Tigray to deliver aid.”

Truck drivers carrying aid into Tigray have been shot at least twice and some Tigrayan drivers have been arrested in the neighboring region of Afar, although they were later released, according to U.N. reports.

Malnutrition

Griffiths said a lot of trucks go into Tigray and don’t come back, compounding the humanitarian problems. He said no fuel trucks had gone into Tigray since late July.

“First of all, they probably don’t have fuel to come out,” he said. “And secondly, they may not wish to, so the consequences for humanitarian operations — whatever the cause — is problematic.”

The United Nations in Ethiopia said on September 16 that only 38 out of 466 trucks that entered Tigray since July 12 had returned. On Tuesday, World Food Program in Ethiopia posted on Twitter that 61 commercial trucks had left Tigray in recent days and they expected more to depart in coming weeks.

“We’ll continue to work with transporters to overcome any logistical issue to ensure trucks are on the road, facilitating the delivery of humanitarian aid,” WFP Ethiopia said.

In Tigray, the United Nations says 5.2 million people, or 90% of the population, need help.

According to the United Nations, screening of children under age 5 during the first half of September revealed that 22.7% of are malnourished and more than 70% of some 11,000 pregnant or breastfeeding women are acutely malnourished.

“As a comparison this is about the same levels of malnutrition that we saw in 2011 in Somalia at the onset of the Somali famine,” Griffiths said.

Griffiths said 100 trucks a day of aid needed to get to Tigray, but only 10% had gained access in the past three months.

“We need the Ethiopian government to do what they promised to do which is to facilitate access,” said Griffiths, who met with Ethiopia’s Deputy Prime Minister Demeke Mekonnen last week during the annual U.N. gathering of world leaders in New York.

Mekonnen assured him that access is improving, but Griffiths said, “it needs to improve a great deal more.”

Source: Voice of America

September 29, 2021

First Female Prime Minister Appointed in Tunisia

Tunisian President Kais Saied surprised many Wednesday with his appointment of Najla Bouden Romdhane, a 63-year-old professor at a prestigious engineering school, as the country’s first female prime minister.

The geologist was named prime minister after the office was vacated July 25 when Saied froze parliament and seized executive powers, leaving the country in limbo.

Saied’s office issued a statement ordering Bouden to fill Cabinet positions as soon as possible.

The president’s moves sidelined the Islamist Party that dominated the legislature, prompting critics to denounce his actions as a coup that jeopardizes the country’s young democracy and could threaten democratic gains made after the Tunisia Revolution that helped spark the Arab Spring in the early 2010s.

The Arab Spring was a sequence of armed, anti-government rebellions and other forms of unrest that swept across much of the Arab world in response to corruption and economic woes.

Last week, Saied suspended most of the constitution, contending he could govern by decree during an indefinite “exceptional” period.

In an online video, he said Bouden’s appointment honored Tunisian women and that the transitional government should address corruption and respond to citizen demands of all sorts, including those pertaining to health, education and transportation.

Bouden may have less power than her predecessors had under the 2014 constitution. Saied said last week when announcing the emergency period that the transitional government would be accountable to the president.

Source: Voice of America